MAINZ BIOMED N.V.MYNZEarnings & Financial Report
Mainz Biomed N.V. is a molecular diagnostics company specializing in the development and commercialization of non-invasive early detection tests for gastrointestinal cancers, primarily colorectal cancer. Its flagship product ColoAlert is approved and available across European markets, with active expansion initiatives targeting North America and other global regions.
MYNZ Q4 FY2023 Key Financial Metrics
Revenue
$214.8K
Gross Profit
$134.7K
Operating Profit
N/A
Net Profit
N/A
Gross Margin
62.7%
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
MAINZ BIOMED N.V. Q4 FY2023 Financial Summary
MAINZ BIOMED N.V. reported revenue of $214.8K for Q4 FY2023, with a net profit of N/A (N/A margin). Cost of goods sold was $80.0K.
Key Financial Metrics
| Total Revenue | $214.8K |
|---|---|
| Net Profit | N/A |
| Gross Margin | 62.7% |
| Operating Margin | N/A |
| Report Period | Q4 FY2023 |
MAINZ BIOMED N.V. Annual Revenue by Year
MAINZ BIOMED N.V. annual revenue history includes year-by-year totals (for example, 2023 revenue was $645.4K).
| Year | Annual Revenue | |
|---|---|---|
| 2023 | $645.4K | — |
MAINZ BIOMED N.V. Quarterly Revenue & Net Profit History
MAINZ BIOMED N.V. results over the last 6 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2023 | $214.8K | — | N/A | N/A |
| Q3 FY2023 | $181.7K | +87.7% | $-6.3M | -3467.7% |
| Q2 FY2023 | $248.9K | +78.8% | $-8.3M | -3314.7% |
| Q1 FY2023 | $1 | — | $-6.6M | -656091600.0% |
| Q3 FY2022 | $96.8K | — | $-5.6M | -5781.8% |
| Q2 FY2022 | $139.2K | — | $-6.9M | -4983.3% |
Income Statement
| Q2 2022 | Q3 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | |
|---|---|---|---|---|---|---|
| Revenue | $139240 | $96791 | $1 | $248945 | $181669 | $214761 |
| YoY Growth | N/A | N/A | N/A | 78.8% | 87.7% | N/A |
Balance Sheet
| Q2 2022 | Q3 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | |
|---|---|---|---|---|---|---|
| Assets | $27.6M | N/A | $19.5M | $19.3M | $17.9M | $15.4M |
| Liabilities | $3.8M | N/A | $9.9M | $14.1M | $14.5M | $12.2M |
| Equity | $23.8M | $20.8M | $9.7M | $5.2M | $3.4M | $3.4M |
Cash Flow
| Q3 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | |
|---|---|---|---|---|---|
| Operating CF | $-3.6M | $-5.7M | $-5.1M | $-6.5M | $-21.9M |